Bodong medical sprint Hong Kong stocks: a 9-month loss of 200million Hillhouse and Philips are shareholders

RedI network   Lei Jianping  2 month 13 Reported Wednesday

Shanghai Bodong Medical Technology Co., Ltd （ abbreviation ：“ Bo Dong Medical ”） The prospectus was submitted a few days ago , Ready to list in Hong Kong .

9 Loss in the first three months 2 Billion

Bodong medical was founded in 2015 year 9 month , It is jointly created by the team of scientists and senior team members of well-known multinational enterprises , The company is headquartered in Xuhui District, Shanghai . 

Bodong medical and Shanghai Jiaotong University 、 National Cardiovascular Center 、 National Cardiovascular Disease Clinical Medicine Research Center 、 Fuwai Hospital, Chinese Academy of Medical Sciences 、 Zhongshan Hospital Affiliated to Fudan University 、 Oxford University, UK 、 Institutions such as the medical school of Aarhus University in Denmark work closely with hospitals , It explores a new direction of accurate diagnostic solutions for computational coronary physiology .

Bodong coronary precise diagnosis product line covers outpatient screening and physical examination for coronary heart disease 、 Accurate diagnosis and PCI Navigation 、 Multimodality of complex coronary intervention guidance IVUS/OCT/QFR Imaging fusion catheter and system .

According to the National Center for cardiovascular disease 《 China cardiovascular health and disease report 2019》 Show , The total number of patients with cardiovascular disease in China has reached 3.3 Billion , among , The number of patients with coronary heart disease exceeds 1100 ten thousand people , Morbidity and mortality are among the highest and still rising .

Usually , After discovering the possibility of suffering from coronary heart disease , Patients need to undergo relevant diagnostic tests . among , Coronary artery CTA Examination is a non-invasive means of examination , Suitable for outpatient or physical examination screening ; Coronary angiography is the most commonly used imaging examination of coronary heart disease , It can dynamically and accurately judge the degree of vascular stenosis ;

Intraluminal imaging （ Intravascular ultrasound IVUS Or optical coherence tomography OCT） It can accurately display the fine structure and plaque nature in blood vessels ; Coronary artery function FFR Check , It can promote the diagnosis of coronary heart disease from “ Structure ” towards “ Functional ” The upgrade .

Tradition FFR It is an invasive vascular interventional examination based on disposable pressure guide wire , Reflect the degree of myocardial ischemia caused by coronary artery stenosis . However , Because of its narrow indications 、 Expensive 、 The operation is complicated 、 Time consuming 、 Intraoperative risks and many other deficiencies , The domestic penetration rate is insufficient 1%.

Bo Dong medicine is called , Its quantitative blood flow fraction (QFR) It is an ultra fast calculation without guide wire based on coronary angiography images FFR Technology , At the same time, there is no need for any additional intervention consumables and vasodilators ,1 The anatomical structure and physiological function evaluation of coronary vessels can be accurately realized within minutes , Whether stent implantation is needed for accurate diagnosis of stenosis before operation 、 Intraoperative guidance of stent selection and virtual stent implantation 、 Judge the treatment effect after operation .

The prospectus shows , Bo Dong Medical 2020 Annual revenue is 3251 Ten thousand yuan , The loss during the period is 93.4 Ten thousand yuan . Bo Dong Medical 2021 Years ago 9 The month's revenue is 5006 Ten thousand yuan , The revenue in the same period last year was 823.8 Ten thousand yuan ; The loss during the period is 2.04 One hundred million yuan , The loss in the same period last year was 747 Ten thousand yuan .

Hillhouse and Philips are shareholders

The executive director of Bodong medical is Ms. Liu Bing ; The non-executive director is Dr. Tu Shengxian 、 Ms. mayingchun 、 Chen Xinxing 、 Xu Xiaoli 、 He Guowei ; The independent non-executive director is Zhou Dongsheng 、 Ms. Zhang Yan 、 Fan Zhichao .

Bo Dong Medical 2020 Total annual completion amount 1.63 One hundred million yuan B Round of funding .

2021 year , Bodong medical completed the acquisition of Suzhou Bodong Rongying , And complete the total amount 6.47 The part of 100 million yuan C Round of funding , This round of financing is jointly led by the old shareholder Hillhouse venture capital and the strategic investor Philips , Goldman Sachs asset management 、 Boyu capital participates in joint investment , Leading capital 、 Old shareholder BoChang capital and other follow-up investment .

Bo Dong medical said , This round of financing funds is used to accelerate the commercialization of the company's products 、 New product development 、 Clinical registration , Further improve the global layout of vascular interventional diagnosis and treatment .

IPO front , Ms. Liu Bing holds 25.6%, Hillhouse Daoheng holds 14.53%, Shanghai Chengye holds 7.43%, Shanghai huiyangyu holds 7%, philips （ China ） The shareholding is 5%, Li Yingguang holds 4.83%, Dr. Tu Shengxian holds 4.57%;

Wuhan Bo hang asked, the shareholding is 4.49%, Shanghai youze holds 4.36%,Eximious Voyager Limited The shareholding is 3.99%, Shaanxi Xike holds 3.37%;

West Street Global Growth Partners II The shareholding is 2.98%, Xuxiaoli holds 2.49%, Suzhou Taifu holds 1.62%, Ms. mayingchun holds 1.54%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .